Tigenix announces change in Board of Directors
Tigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.
Following the successful result of the first acceptance period of the takeover bid by Takeda, Eduardo Bravo will be succeeded as a member of the board of directors by Sebastian Wehle. Sebastian will also be in charge of the daily management of TiGenix together with Claudia D’Augusta, CFO of Tigenix. Consequently, the services agreement between Tigenix and Eduardo Bravo will be terminated effective as of June 15, 2018.
"Eduardo’s contribution to Tigenix cannot be overstated", said Jean Stéphenne, Chairman of Tigenix’s board of directors. "Working closely with the management team and the board of directors, Eduardo guided Tigenix over the past 13 years into a position of considerable strength within the cell therapy space.
The appointment of Sebastian Wehle is effective immediately, subject to confirmation by the next shareholders’ meeting of Tigenix.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium